John Gerecitano

John Gerecitano, MD, PhD, is the Senior Vice President of Oncology Research and Development at Sana Biotechnology. Prior to Sana, John served as the Global Medical Head of the Lymphoma Disease Area Stronghold at Johnson & Johnson Innovative Medicine. From 2006 to 2018, John was a practicing oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC) and served as the Clinical Director of Lymphoma Care at MSKCC starting in 2014. John was also a founding member of the Phase 1 Clinical Trials Program for Solid Tumors and Lymphoma at MSKCC. During his 11 years on the faculty of MSKCC and Weil Cornell Medical College, John was the Principal Investigator (PI) of over 20 Phase 1 trials, as well as the Global PI of the Phase 3 CHRONOS 3 trial. John completed his internal medicine training at the Hospital of the University of Pennsylvania and his fellowship in hematology/oncology at MSKCC. He obtained a BS in Human Development and Family Studies from Cornell University and an MD, PhD (microbiology) from New York University School of Medicine.